EyeGene,Inc
KOSDAQ-listed biotech venture developing mRNA vaccines, AAV gene therapies, and the EG-MCV4 meningococcal vaccine.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2015, EyeGene is a biotech venture specializing in gene and cell therapies (GCT) and vaccines. Its pipeline includes an mRNA vaccine (Capless saRNA platform), AAV gene therapies targeting macular degeneration and diabetic retinopathy, the quadrivalent meningococcal conjugate vaccine EG-MCV4, and the recombinant botulinum toxin EG-rBTX100. Its mRNA vaccine, developed since 2020, has completed Phase 1/2a trials domestically and abroad with a co-development consortium of 5 partner companies; EG-MCV4 has completed domestic Phase 2 trials and is preparing for Phase 3, targeting domestic military procurement and entry into Latin America (PAHO) and Southeast Asia from 2028; and EG-rBTX100 is being developed with Korea BMI, with clinical trials planned from 2027.
Regulatory approvals
data.go.kr3 Korean MFDS device approvals · 2023–2026
- MFDSGraft/prosthesis, biomaterial2026-02-12Product approval · Class 4제허 26-142 호
- MFDSGraft/prosthesis, biomaterial2025-01-21Product approval · Class 4제허 25-45 호
- MFDSGeneral gene amplificator, nucleic acid, without fluorescence meter2023-11-27Product approval · Class 1체외 제신 23-1694 호
Clinical trials
data.go.kr8 MFDS clinical trial authorisations · 2012–2025 (Phase 2 2 · Phase 1 2 · Phase 2/3 1 · Phase 1/2a 1 · Phase 2a 1)
- Phase 2/3EG-MCV42025-06-30
13 trial sites
- Phase 1/2aEG-COVID2021-08-31
2 trial sites
- Phase 2EG-Mirotin2020-03-12
1 trial site
- Phase 2EG-Myocin2019-02-19
9 trial sites
- Phase 2aEG-Decorin 연고2018-10-30
1 trial site
- Phase 1EG-Myocin2017-11-28
1 trial site
- Phase 1/2EG-Decorin 연고2013-01-21
10 trial sites
- Phase 1EG-HPV2012-09-10
1 trial site
R&D and key agreements
Source: DART corporate disclosuremRNA 백신(Capless saRNA) · 코로나19 등 감염병 · 임상 1/2a상 완료(2020년부터 개발), 차세대 백신 개발중 · Consortium formed with 5 domestic and international partners; uses a new LNP delivery system
AAV 유전자치료제 · 황반변성, 당뇨망막증, 희귀 망막질환 · 연구개발중 · Aims for long-term efficacy from a single administration
EG-MCV4(4가 수막구균 접합백신) · 수막구균 감염 · 국내 임상 2상 완료, 3상 준비중 · Plans domestic military procurement and entry into Latin America (PAHO) and Southeast Asia from 2028; developed with Korea BMI
EG-rBTX100(유전자재조합 보툴리눔톡신) · 보툴리눔톡신 적응증 · 비임상 시험중, 2027년 임상 계획 · Developed with Korea BMI; pursuing licensing-out deals in parallel
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
Founded in 2013 and KOSDAQ-listed in 2018, T&R Biofab commercializes 3D bioprinting systems, bioinks, and biodegradable scaffolds.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition